人 CEBPA 抗体对
01AB01652
CCAAT enhancer binding protein alpha (CEBPA) is an intronless gene encoding a basic leucine zipper (bZIP) transcription factor that regulates gene expression by binding CCAAT-containing promoter elements as homodimers or heterodimers. Highly expressed in myeloid progenitors, adipocytes, and hepatocytes, CEBPA coordinates cell-cycle arrest and terminal differentiation by repressing E2F1 and interacting with the SWI/SNF complex. It is essential for granulocyte and monocyte lineage commitment, adipogenesis, and hepatic glucose and lipid metabolism. Mutations in CEBPA, particularly those affecting the N-terminal transactivation or C-terminal bZIP domains, impair DNA binding and block myeloid differentiation. Such mutations are a hallmark of a distinct subtype of acute myeloid leukemia (AML), which is recognized as a specific clinical entity often associated with a favorable prognosis.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- CEBPA
- 基因别名
- CEBP
- 蛋白别名
- CCAAT enhancer binding protein alpha; CEBPA
- UniProt
- P49715
- 物种
- Human
产品详情
- 靶点名称
- CEBPA
- 蛋白名称
- CCAAT enhancer binding protein alpha
- 蛋白别名
- CCAAT/enhancer-binding protein alpha; C/EBP alpha
- 靶点基因名
- CEBPA
- 基因别名
- CEBP
- UniProt
- P49715
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
CCAAT enhancer binding protein alpha (CEBPA) is an intronless gene encoding a basic leucine zipper (bZIP) transcription factor that regulates gene expression by binding CCAAT-containing promoter elements as homodimers or heterodimers. Highly expressed in myeloid progenitors, adipocytes, and hepatocytes, CEBPA coordinates cell-cycle arrest and terminal differentiation by repressing E2F1 and interacting with the SWI/SNF complex. It is essential for granulocyte and monocyte lineage commitment, adipogenesis, and hepatic glucose and lipid metabolism. Mutations in CEBPA, particularly those affecting the N-terminal transactivation or C-terminal bZIP domains, impair DNA binding and block myeloid differentiation. Such mutations are a hallmark of a distinct subtype of acute myeloid leukemia (AML), which is recognized as a specific clinical entity often associated with a favorable prognosis.